Sourcing analytical-grade Thymosin Alpha 1 for laboratory research requires uncompromising purity standards, lot-specific verification, and reliable domestic supply chains. PX1 Research provides synthetic Thymosin Alpha 1 manufactured under stringent quality controls, fully documented via independent third-party analysis for qualified preclinical research applications.
Sourcing analytical-grade Thymosin Alpha 1 for laboratory research requires uncompromising purity standards, lot-specific verification, and reliable domestic supply chains. PX1 Research provides synthetic Thymosin Alpha 1 manufactured under stringent quality controls, fully documented via independent third-party analysis for qualified preclinical research applications.
High-purity Thymosin Alpha 1 peptide for sale is available through PX1 Research as a lyophilized research-grade compound intended strictly for in vitro assays, cellular culture, and preclinical laboratory experimentation. Every lot undergoes independent third-party RP-HPLC and mass spectrometry verification to guarantee chemical purity exceeding 98% alongside sub-0.1 EU/mg endotoxin limits.
When purchasing synthetic peptides for experimental protocols, investigators must prioritize verified sequence identity, physical stability, and freedom from residual synthesis reagents. Lower-grade raw materials or unverified preparations introduce confounding variables into immunological and cellular assays. PX1 Research addresses these requirements by supplying fully characterized Thymosin Alpha 1 research peptide reagents backed by transparent, downloadable Certificates of Analysis (COAs) for every lot.
Thymosin Alpha-1 (Tα1) is an endogenous 28-amino acid peptide originally isolated from bovine thymic tissue (Thymosin Fraction 5) and subsequently produced via solid-phase peptide synthesis (SPPS) for controlled biochemical evaluation. Its primary structure consists of the sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH, with an N-terminal acetylation that confers enhanced enzymatic stability against aminopeptidases in solution.
With a calculated molecular weight of approximately 3108.3 Da, Tα1 exhibits an acidic isoelectric point due to a high concentration of glutamic and aspartic acid residues. In aqueous buffer solutions at physiological pH, the peptide adopts a largely unstructured conformation in free state but transitions into amphipathic alpha-helical domains upon interaction with specific membrane lipids or receptor complexes. These structural dynamics govern its binding affinity to target cell surfaces in preclinical models.
In vitro data indicate that Thymosin Alpha-1 acts primarily through interaction with Toll-like receptors (TLRs), specifically TLR2, TLR7, and TLR9, located on dendritic cells and monocytes. Binding to these pattern recognition receptors initiates intracellular signaling cascades driven by the MyD88 (Myeloid Differentiation Primary Response 88) adaptor protein.
Preclinical studies suggest that MyD88 activation by Tα1 downstream triggers nuclear factor kappa B (NF-κB) and p38 mitogen-activated protein kinase (MAPK) translocation. This transcriptional activation modulates the expression of various cytokines, upregulating interleukin-2 (IL-2), interleukin-12 (IL-12), and interferon-gamma (IFN-γ) in lymphocyte populations. Investigators evaluating intracellular signal transduction frequently utilize Tα1 to study signal amplification in immunocompetent versus immunosuppressed cell lines.
In cell-culture assays, Tα1 has been shown to induce maturation of early T-cell precursors into phenotypically mature CD4+ and CD8+ T lymphocytes. Animal models demonstrate that administration of synthetic Tα1 increases the expression of high-affinity IL-2 receptors (CD25) on active T-cells, enhancing localized proliferative responses without inducing systemic inflammatory responses.
Furthermore, preclinical research highlights Tα1's capacity to upregulate major histocompatibility complex (MHC) Class I expression on viral-infected or transformed target cells, rendering them more recognizable to cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. Researchers investigating viral dynamics, oncology models, and immune senescence utilize this peptide to assess cell-mediated immune responses in controlled laboratory settings. Browse our broader catalog of research peptides to examine complementary compounds active in signaling and cellular regulation pathways.
When designing comparative research protocols targeting tissue repair, cell maturation, or inflammatory modulation, principal investigators frequently contrast Tα1 with other synthetic peptides. While Tα1 focuses on adaptive immune signaling and TLR pathway stimulation, compounds like Thymosin Beta-4 exert primary effects on actin polymerization, cell migration, and tissue remodeling mechanisms. Conversely, small regulatory peptides such as KPV peptide act primarily through nuclear translocation of NF-κB suppression to reduce pro-inflammatory signals, whereas cytoprotective agents like BPC-157 target angiogenic pathways and nitric oxide modulation in localized tissue models.
Understanding these distinct operational mechanisms allows researchers to select the precise peptide or combination matrix required for their specific hypothesis. While Tα1 provides a targeted probe for T-cell differentiation and dendritic cell activation, alternative peptide families offer specialized utility in cellular migration or extracellular matrix maintenance assays. For comprehensive literature reviews on these mechanisms, explore our immunomodulatory research peptides resource section.
The integrity of preclinical data depends entirely on the analytical purity of the biological reagents employed. Substandard synthesis can leave truncation sequences, unreacted amino acid derivatives, or counterion contaminants that alter cellular kinetics and distort assay readouts. PX1 Research subjects every batch of Thymosin Alpha 1 to rigorous dual-stage testing in ISO 17025 accredited laboratories.
Purity is quantitatively assessed using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a baseline chemical purity of ≥98%. Exact molecular weight and sequence identity are confirmed via Liquid Chromatography-Mass Spectrometry (LC-MS) electrospray ionization. Furthermore, because Tα1 is frequently evaluated in sensitive cell culture systems, every lot is subjected to Chromogenic Recombinant Factor C (rFC) testing to guarantee bacterial endotoxin levels remain strictly below 0.1 EU/mg, preventing non-specific innate immune activation during experiments. Review our guide on analytical purity testing for deeper methodology details.
Thymosin Alpha 1 is delivered as a sterile, lyophilized cake inside sealed borosilicate glass vials to prevent moisture ingress and oxidation. For optimal long-term stability, unopened vials must be stored at -20°C or -80°C in a desiccated environment, shielded from light exposure.
Reconstitution should be conducted under a laminar flow hood using sterile laboratory-grade solvents such as Bacteriostatic Water (0.9% benzyl alcohol) or sterile 0.9% Sodium Chloride solution depending on assay compatibility. Gentle swirling without vortexing is recommended to fully dissolve the peptide mass while avoiding shear-induced aggregation. Following reconstitution, stock solutions should be aliquoted into single-use polypropylene microtubes and stored at -20°C or lower to avoid repeated freeze-thaw cycles. Detailed step-by-step procedures are outlined in our dedicated reconstitution guidelines.
Acquiring high-purity peptides with reliable lot traceability is essential for maintaining project timelines and reproducible findings. PX1 Research operates fully domestic, GMP-compliant synthesis and distribution hubs located in California and Arizona, providing rapid dispatch and eliminating international customs delays or cold-chain disruptions.
Orders placed before 12:00 PM PST Monday through Friday are processed for same-day dispatch. Institutional buyers, university laboratories, and contract research organizations (CROs) requiring multi-gram quantities or custom synthesis lots can access scaled pricing models through our specialized bulk peptide procurement channel.
What is the certified purity level of PX1 Research Thymosin Alpha 1?
PX1 Research guarantees a minimum chemical purity of 98.0% for Thymosin Alpha 1, verified via high-performance liquid chromatography (RP-HPLC) and liquid chromatography-mass spectrometry (LC-MS).
What endotoxin thresholds apply to PX1 Thymosin Alpha 1 lots?
Every lot is tested for bacterial endotoxins using validated chromogenic assays, ensuring levels remain strictly below 0.1 EU/mg to prevent confounding background inflammatory responses in cell culture assays.
How should lyophilized Thymosin Alpha 1 be stored upon arrival?
Lyophilized powder should be stored at -20°C upon receipt. Protect the product from light and moisture ingress. Under these conditions, the dry peptide remains stable for up to 24 months.
Which solvents are recommended for reconstituting Thymosin Alpha 1?
For standard laboratory applications, sterile reconstitution solution, sterile 0.9% saline, or phosphate-buffered saline (PBS, pH 7.4) are commonly utilized depending on specific cell culture sensitivity.
Where is PX1 Research Thymosin Alpha 1 manufactured and shipped from?
All PX1 Research compounds are manufactured in US-based, GMP-compliant facilities and shipped directly from fulfillment centers in California and Arizona.
Is a Certificate of Analysis (COA) included with my order?
Yes. Every order includes access to a lot-specific Certificate of Analysis detailing HPLC chromatograms, mass spectrometry profiles, and endotoxin assay results.
Can Thymosin Alpha 1 be used in human clinical applications?
No. Products sold by PX1 Research are strictly designated for laboratory research, in vitro experimentation, and preclinical scientific study. They are not for human consumption, medical, or diagnostic use.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.